PSVT


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.

tachycardia

 [tak″e-kahr´de-ah]
abnormally rapid heart rate, usually taken to be over 100 beats per minute. adj., adj tachycar´diac.
A, Sinus tachycardia; B, Ventricular tachycardia. From Chernecky, 2001.
antidromic circus movement tachycardia a supraventricular tachycardia supported by a reentry circuit that uses the atrioventricular node in the retrograde direction and an accessory pathway in the anterograde direction; this produces a broad QRS rhythm indistinguishable from ventricular tachycardia. Such a tachycardia may also use two accessory pathways (one anterograde and one retrograde) and not involve the AV node at all.
atrial tachycardia a rapid heart rate, between 140 and 250 beats per minute, with the ectopic focus in the atria and with no participation by the atrioventricular node or the sinoatrial node. It is recognizable on the electrocardiogram because the P wave precedes the QRS complex, as opposed to being merged with it or following it. This condition is usually associated with atrioventricular block or digitalis toxicity.
benign ventricular tachycardia tachycardia originating in the ventricles, not associated with structural heart disease or significant hemodynamic symptoms.
bidirectional ventricular tachycardia (bifascicular ventricular tachycardia) a ventricular arrhythmia characterized by heart rates of 90 to 160 beats per minute, alternating right and left axis deviation, ectopic focus that alternates between the anterior superior and posterior inferior fascicles, and a right bundle branch block pattern in lead V1; seen in digitalis toxicity and other conditions.
chaotic atrial tachycardia an ectopic atrial tachycardia due to multifocal activity, characterized by at least three different shapes of P waves on the electrocardiogram; often associated with chronic obstructive lung disease.
circus movement tachycardia (CMT) a reentry circuit that uses an accessory pathway or pathways; there are two subtypes, antidromic and orthodromic circus movement tachycardia.
ectopic tachycardia rapid heart action in response to impulses arising outside the sinoatrial node.
junctional tachycardia rhythm at the rate of 100 to 140 beats per minute that arises in response to impulses originating in the atrioventricular junction, i.e., the atrioventricular node. It is often seen with digitalis toxicity and is due to triggered activity, but it may also be due to altered automaticity. In the case of digitalis toxicity, the term may be used to encompass the entire span of junctional rates with this condition, i.e., approximately 70 to 140 beats per minute.
monomorphic ventricular tachycardia a type that has a uniform beat-to-beat QRS morphology.
nonsustained ventricular tachycardia a type that terminates spontaneously within 30 seconds and does not lead to hemodynamic collapse.
orthodromic circus movement tachycardia a supraventricular tachycardia supported by a reentry circuit that uses the atrioventricular node in the anterograde direction and an accessory pathway in the retrograde direction, producing a narrow QRS complex.
orthostatic tachycardia disproportionate rapidity of the heart rate on arising from a reclining to a standing position.
paroxysmal tachycardia rapid heart action that starts and stops abruptly.
paroxysmal atrial tachycardia paroxysmal supraventricular tachycardia.
paroxysmal supraventricular tachycardia (PSVT) a narrow QRS tachycardia that begins and ends abruptly; it may be terminated with a vagal maneuver. It has two common mechanisms, atrioventricular nodal reentry and circus movement that uses the atrioventricular node anterogradely and an accessory pathway retrogradely. On the electrocardiogram it is characterized by abrupt onset, and mechanisms are differentiated by the relation of the P wave to the QRS complex.
polymorphic ventricular tachycardia a type that has a constantly, and sometimes subtly, changing beat-to-beat QRS configuration.
potentially malignant ventricular tachycardia a type that is not associated with structural heart disease or hemodynamically important cardiac symptoms but is sometimes associated with left ventricular dysfunction.
sinus tachycardia (ST) a rapid rhythm originating in the sinoatrial node with a rate of usually 100 to 160 beats per minute; conduction through the ventricles is normal. During exercise or stress this is normal, but if it occurs during rest it is abnormal.
supraventricular tachycardia a combination of junctional tachycardia and atrial tachycardia.
sustained ventricular tachycardia tachycardia that lasts more than 30 seconds and leads to hemodynamic collapse.
ventricular tachycardia an abnormally rapid ventricular rhythm with aberrant ventricular excitation, characterized by at least three consecutive ventricular complexes of more than 100 beats per minute. It is generated within the ventricle and is most often associated with atrioventricular dissociation.

PSVT

paroxysmal supraventricular tachycardia.

PSVT

paroxysmal supraventricular tachycardia.
See: tachycardia
References in periodicals archive ?
Over the past two months, several teams have reported dramatic success using radio waves to eliminate the aberrant electrical conduits in PSVT patients.
People born with a susceptibility to this common form of PSVT possess an extra fibrous circuit connecting the heart's upper and lower chambers.
This Phase 1 study validates the product concept because a prolongation of the PR interval as measured by ECG is associated with modulation of the atrio-ventricular (AV) node in the heart, which underlies the pathology in PSVT.
These results suggest MSP-2017 can impact AV nodal conduction, and support the potential of MSP-2017 to treat PSVT episodes.
Cordex intends to initiate prospective, double-blind, placebo-controlled and randomized clinical trials with its lead product ATPace(TM) in approximately 200 patients aimed at demonstrating clinical safety and efficacy sufficient to support a New Drug Application filing of ATPace(TM) for the treatment of PSVT in emergency room patients.
Cordex has recently announced the submission to the FDA of an amended Phase 3 clinical trial protocol with ATPace as an antiarrhythmic drug for the conversion of PSVT to normal sinus rhythm.
Currently, adenosine is the only approved drug for the acute treatment of PSVT in the United States.
There are approximately 570,000 persons with PSVT in the United States alone, with an estimated 89,000 new cases diagnosed each year.
It has been estimated that there are 89,000 new cases of PSVT per year and approximately 570,000 persons with PSVT in the United States alone.
It has been estimated that there are 89,000 new cases of PSVT annually and approximately 570,000 persons overall with PSVT in the U.
Duska intends to initiate a single, prospective, placebo-controlled, and randomized trial in patients presenting to the emergency room with PSVT to demonstrate ATPace's clinical safety and efficacy.